Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.8%

39 terminated/withdrawn out of 87 trials

Success Rate

31.6%

-54.9% vs industry average

Late-Stage Pipeline

7%

6 trials in Phase 3/4

Results Transparency

139%

25 of 18 completed trials have results

Key Signals

11 recruiting25 with results17 terminated22 withdrawn

Enrollment Performance

Analytics

Phase 1
50(59.5%)
Phase 2
28(33.3%)
Phase 3
6(7.1%)
84Total
Phase 1(50)
Phase 2(28)
Phase 3(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (87)

Showing 20 of 87 trials
NCT06765954Phase 2Withdrawn

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Role: lead

NCT06745908Phase 3Recruiting

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Role: lead

NCT06765902Phase 2Withdrawn

Immunotherapy Before and After Surgery

Role: lead

NCT07524257Phase 3Not Yet Recruiting

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

Role: lead

NCT06334991Phase 1Recruiting

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Role: lead

NCT07125872Phase 2Recruiting

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Role: lead

NCT05981131Active Not Recruiting

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Role: lead

NCT07488884Phase 1Not Yet Recruiting

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Role: lead

NCT07556757Phase 1Recruiting

A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

Role: lead

NCT07551544Phase 3Not Yet Recruiting

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

Role: lead

NCT03520686Phase 3Terminated

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Role: lead

NCT05304936Phase 1Completed

HCW9218 for Advanced Pancreatic Cancer

Role: lead

NCT05618925Phase 1Recruiting

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Role: lead

NCT07049432Phase 1Withdrawn

N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Role: collaborator

NCT04050709Phase 1Completed

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Role: lead

NCT02138734Phase 1Active Not Recruiting

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Role: lead

NCT06800963Phase 1Recruiting

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

Role: lead

NCT06810141Unknown

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Role: lead

NCT07108036Phase 2Recruiting

A Study to Assess Anktiva in Patients With Long Covid-19.

Role: lead

NCT07492875Phase 3Not Yet Recruiting

Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

Role: lead